BIP Wealth LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY)

BIP Wealth LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 45.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 896 shares of the company’s stock after purchasing an additional 280 shares during the period. BIP Wealth LLC’s holdings in Eli Lilly and Company were worth $522,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. International Assets Investment Management LLC raised its stake in Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after acquiring an additional 7,330,815 shares during the last quarter. Sapient Capital LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at approximately $435,736,000. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after acquiring an additional 645,473 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on the company. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Bank of America boosted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday, April 15th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Price Performance

LLY stock traded down $7.48 on Thursday, reaching $724.72. The company had a trading volume of 1,698,612 shares, compared to its average volume of 3,021,339. Eli Lilly and Company has a 1 year low of $370.68 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company’s fifty day moving average is $763.40 and its 200 day moving average is $664.52. The company has a market cap of $688.60 billion, a P/E ratio of 124.61, a PEG ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the prior year, the company earned $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.